Guiyou Tian

Guiyou Tian

Auto-generated profile, based on publicly available information

Guiyou Tian

Bio-pharmaceutical Lab, Life Science College, Northeast Agricultural University, Harbin 150030, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
YYYinhang Yu
Yinhang Yu
FBFuliang Bai
Fuliang Bai
WWWenfei Wang
Wenfei Wang
YLYaonan Liu
Yaonan Liu
QYQingyan Yuan
Qingyan Yuan
GRGuiping Ren
Guiping Ren

1 August 2020 in Molecular Cell
Verified
Journal Article
Closed access
YLYingying Lin
Yingying Lin
FLFajin Li
Fajin Li
LHLinlu Huang
Linlu Huang
CPChristine Polte
Christine Polte
HDHaoran Duan
Haoran Duan
DWDieter Wolf
Dieter Wolf

21 February 2015 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
YYYinhang Yu
Yinhang Yu
FBFuliang Bai
Fuliang Bai
YLYaonan Liu
Yaonan Liu
YYYongbi Yang
Yongbi Yang
QYQingyan Yuan
Qingyan Yuan
DLDeshan Li
Deshan Li

1 March 2015 in International Immunopharmacology
Verified
Journal Article
Closed access
YYYinhang Yu
Yinhang Yu
SLSiming Li
Siming Li
YLYaonan Liu
Yaonan Liu
GTGuiyou Tian
Guiyou Tian
QYQingyan Yuan
Qingyan Yuan
DLDeshan Li
Deshan Li

19 May 2021 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
GTGuiyou Tian
Guiyou Tian
CHCheng Hu
Cheng Hu
YYYun Yun
Yun Yun
WYWensheng Yang
Wensheng Yang
WDWolfgang Dubiel
Wolfgang Dubiel
DWDieter Wolf
Dieter Wolf
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

9 July 2016 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
GRGuiping Ren
Guiping Ren
GTGuiyou Tian
Guiyou Tian
YLYunye Liu
Yunye Liu
JHJinjiao He
Jinjiao He
XGXinyu Gao
Xinyu Gao
DLDeshan Li
Deshan Li
Interleukins as immunomodulators are promising therapeutic agents for cancer therapy. Previous studies showed that there was an improved antitumor immunity in tumor-bearing mice using recombinant Newcastle disease virus carrying for interleukin-2. Interleukin-12 is a promising antitumor cytokine too. So we investigated and compared the antitumor effect of genetically engineered Newcastle disease virus strains expressing both interleukin-12 and/or interleukin-2 (rClone30–interleukin-2, rClone30–interleukin-12, and rClone30–interleukin-12–interleukin-2). In vitro studies showed that rClone30s could efficiently infect tumor cells and express interleukin-12 and/or interleukin-2. 3-(4,5-Dimethylthiazol-2-y)-2,5-diphenyl-tetrazolium bromide results showed rClone30s possessed strong cytotoxic activities against multiple tumor cell lines (U251, HepG2, A549, and Hela). Animal studies showed that rClone30–interleukin-12–interleukin-2 was more effective in inhibition of murine hepatoma carcinoma tumors, with the mean tumor volume (day 14) of 141.70 mm3 comparing 165.67 mm3 of rClone30–interleukin-12 group, 210.47 mm3 of rClone30–interleukin-2 group, 574.70 mm3 of rClone30 group, and 1206.83 mm3 of phosphate-buffered saline group. Moreover, the rClone30–interleukin-12–interleukin-2 treated mice secreted more interferon γ (333.518 pg/mL) and its downstream cytokine interferon-γ induced protein 10 (16.006 pg/mL) in tumor than the rClone30–interleukin-12 group (interferon γ: 257.548 pg/mL; interferon-γ induced protein 10: 13.601 pg/mL), rClone30–interleukin2 group (interferon γ: 124.601 pg/mL; interferon-γ induced protein 10: 9.779 pg/mL), or rClone30 group (interferon γ: 48.630 pg/mL; interferon-γ induced protein 10:1.650 pg/mL). For the survival study, rClone30–interleukin12–interleukin2 increased the survival rate (12 of 16) of the tumor-bearing mice versus 11 of 16 in rClone30–interleukin–12 group, 10 of 16 in rClone30–interleukin-2 group, 7 of 16 in Clone30 group, and 0/16 in phosphate-buffered saline group, respectively. To determine whether the mice treated with recombinant virus developed protective immune response, the mice were rechallenged with the same tumor cells. The results showed that viral-treated mice were significantly protected from rechallenge. These results suggest that expressing both interleukin-2 and/or interleukin-12 could be ideal approaches to enhance the antitumor ability of Newcastle disease virus, and rClone30–interleukin-12–interleukin-2 is slightly superior over rClone30–interleukin-12 and rClone30–interleukin-2 alone.